Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
Burden of hospitalizations in four adolescent and young adult (AYA) cancer survivor populations in the United States, 2006-2020.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wernli Karen J, Haupt Eric C, Smitherman Andrew B, Osuji Thearis, Shen Ernest, Chawla Neetu, Casperson Mallory, Kirchhoff Anne C, Laurent Cecile A, Ruddy Kathryn J, Keegan Theresa H M, Kaddas Heydon K, Abrahão Renata, Chao Chun R, Sauder Candice A M, Figueroa Gray Marlaine, Chubak Jessica, Nichols Hazel B, Kushi Lawrence H, Hahn Erin E
Аннотация
BACKGROUND: We describe hospitalization rates in adolescent and young adult (AYA) cancer survivors 2-5 years (Y2-Y5) from diagnosis.
METHODS: Observational study of AYA cancer survivors diagnosed 2006-2020 was conducted in two healthcare systems [Kaiser Permanente Southern California (n=7889) and Northern California (n=7338)] and two states [California (47,302) and Utah (n=7935)]. Hospitalizations were ascertained from electronic health records and statewide administrative records and stratified by whether pregnancy-related. Hospitalization rates were calculated by cohort. We estimated patient factors associated with hospitalizations using a Poisson model.
RESULTS: Most AYA survivors were women (~64% of all cohorts), mean age ~31 years at diagnosis, and non-Hispanic white (range 35.1-81.2%) or Hispanic (range 14.3-40.6%). Overall, 21-24% of AYA survivors experienced >1 hospitalization. Unadjusted hospitalization rates declined from Y2 [range 155.1-243.4 per 1000 person-years (PY)] to Y5 (range 105.8-132.0 PY) (p-trend<0.0001 in all cohorts). Factors associated with increased non-pregnancy related hospitalizations were [range of relative risks (RR)]: non-Hispanic Black race/ethnicity (RR 1.46-1.66 vs non-Hispanic white); public insurance (RR 1.57-1.93 vs commercial/military); receipt of chemotherapy (RR 1.51-1.81), and cancer type-breast (RR 1.69-1.97), cervical (RR 2.30-3.31), colorectal (2.76-3.66), acute lymphoblastic leukemia (RR 2.89-5.19), acute myeloid leukemia (2.11-5.05), and sarcoma (RR 2.70-4.96) (vs thyroid).
CONCLUSIONS: While hospitalizations decline as time from diagnosis elapses across health system settings and states, nearly 1 in 5 AYA cancer survivors experience hospitalization in early survivorship.
, IMPACT: Hospitalization rates remain elevated in some AYA patient subgroups in early survivorship, highlighting the need to identify AYAs at risk to mitigate unanticipated hospitalizations and costs.
METHODS: Observational study of AYA cancer survivors diagnosed 2006-2020 was conducted in two healthcare systems [Kaiser Permanente Southern California (n=7889) and Northern California (n=7338)] and two states [California (47,302) and Utah (n=7935)]. Hospitalizations were ascertained from electronic health records and statewide administrative records and stratified by whether pregnancy-related. Hospitalization rates were calculated by cohort. We estimated patient factors associated with hospitalizations using a Poisson model.
RESULTS: Most AYA survivors were women (~64% of all cohorts), mean age ~31 years at diagnosis, and non-Hispanic white (range 35.1-81.2%) or Hispanic (range 14.3-40.6%). Overall, 21-24% of AYA survivors experienced >1 hospitalization. Unadjusted hospitalization rates declined from Y2 [range 155.1-243.4 per 1000 person-years (PY)] to Y5 (range 105.8-132.0 PY) (p-trend<0.0001 in all cohorts). Factors associated with increased non-pregnancy related hospitalizations were [range of relative risks (RR)]: non-Hispanic Black race/ethnicity (RR 1.46-1.66 vs non-Hispanic white); public insurance (RR 1.57-1.93 vs commercial/military); receipt of chemotherapy (RR 1.51-1.81), and cancer type-breast (RR 1.69-1.97), cervical (RR 2.30-3.31), colorectal (2.76-3.66), acute lymphoblastic leukemia (RR 2.89-5.19), acute myeloid leukemia (2.11-5.05), and sarcoma (RR 2.70-4.96) (vs thyroid).
CONCLUSIONS: While hospitalizations decline as time from diagnosis elapses across health system settings and states, nearly 1 in 5 AYA cancer survivors experience hospitalization in early survivorship.
, IMPACT: Hospitalization rates remain elevated in some AYA patient subgroups in early survivorship, highlighting the need to identify AYAs at risk to mitigate unanticipated hospitalizations and costs.